Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPOCH-R-B Induction and Bortezomib Maintenance in Untreated Mantle Cell Lymphoma
NCT00114738Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jun 2005
- Primary completion
- Aug 2016
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in mantle cell lymphoma (MCL) comparing Bortezomib Maintenance with Observation (2 arms). Primary endpoints: Progression Free Survival at 5 years, Overall Survival at 9.9 years and 1 more. Started Jun 2005; status: completed.
02
Drugs
bortezomib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT00114738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00114738.